Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 4/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637860 | 1.00 | RIPK1 (0.35) | RIPK1EPHX2HTR2AHTR2CKMT2A | |
| SCHEMBL2554327 | 0.86 | RIPK1 (0.48) | RIPK1EPHX2KMT2ALMNAANPEP | |
| SCHEMBL30600788 | 0.84 | RIPK1 (0.35) | RIPK1EPHX2KMT2AANPEPNPC1 | |
| SCHEMBL20517454 | 0.84 | RIPK1 (0.35) | RIPK1EPHX2KMT2AANPEPNPC1 | |
| SCHEMBL557943 | 0.84 | P2RX7 (0.43) | KMT2ACFDNPC1RAB9AP2RX7 | |
| SCHEMBL31248715 | 0.80 | LMNA (0.36) | RIPK1EPHX2KMT2ALMNAP2RX7 | |
| SCHEMBL559409 | 0.78 | P2RX7 (0.33) | RIPK1EPHX2HTR2AKMT2AP2RX7 | |
| SCHEMBL21435088 | 0.78 | P2RX7 (0.38) | RIPK1KMT2ALMNARAB9AP2RX7 | |
| SCHEMBL26933002 | 0.78 | P2RX7 (0.42) | RIPK1EPHX2KMT2ALMNAP2RX7 | |
| SCHEMBL21634892 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | IP2IPO INNOVATIONS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| WO-2023218195-A1 | GCN2 INHIBITORR | IP2IPO INNOVATIONS LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218195-A1 | GCN2 INHIBITORR | IP2IPO INNOVATIONS LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | EIF2AK4, GCN1, GCGR | RIPK1 4171/4885EPHX2 2565/4885HTR2A 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.